We are advised by Celltrion USA that journalists and other readers should disregard the news release, Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary, issued 28-Aug-2024 over PR Newswire.

Source : CISION PR Newswire - /DISREGARD RELEASE: Celltrion USA/ https://www.prnasia.com/story/archive/4492006_CN92006_0